For research use only. Not for use in humans.

Sintilimab (anti-PD-1)

Synonyms: IBI 308 Cat.No.A2035 Purity:98.93%

Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.

Click to purchase the isotype control of

1 Citation

17 Nobel Prize winners
have used Selleck products

Shimon Sakaguchi

Nature Communications 2025;16, Article number:1325

David Baker

Dev Cell 2023;58(20):2163-2180.e9.

Michael Houghton

Cell Chem Biol 2020;27(7):780-792.e5

David Julius

Cell 2017;185-198.e16

Charles M. Rice

Cell 2018;172(3):423-438.e25

Quality Control

Batch: Purity: 98.93% Protein concentration: 5 mg/ml Endotoxin Level: <1EU/mg

98.93

Specificity

Name	Citation	PD-1/PD-L1 interaction
PD-1/PD-L1 Inhibitor 3	13	+++
BMS-1	13	++
BMS-202	26	+
AUNP-12	3	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
References	[1] https://pubmed.ncbi.nlm.nih.gov/33324564/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2072873-06-2
Isotype	Human IgG4, κ
Source	CHO cells
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.